GENE ONLINE|News &
Opinion
Blog

2020-09-14| M&ATrials & Approvals

Gilead Strengthens its Oncology Portfolio with Acquisition of Immunomedics

by Judy Ya-Hsuan Lin
Share To

Gilead is ambitious in expanding its oncology portfolio, as it has made deals with three different pharmaceutical companies so far this year. Gilead recently acquired Immunomedics for $21 billion when the two parties signed a joint statement on September 13th.

By Judy Ya-Hsuan Lin

Months ago, Gilead purchased a 49.9% stake in cancer developer Pionyr Immunotherapeutics in June for $275 million and paid $4.9 billion for Forty Seven Inc. which is the creator of an experimental treatment targeting blood cancer. All these acquisitions give Gilead a strong foothold in the fast-growing cancer drug market.

On September 11th, Gilead offered about double the value of Immunomedics’s last closing price of $42.25 per share to acquire it for a total of $21 billion. The transaction is expected to close in the fourth quarter of this year, mainly granting Gilead access to Immunomedics’ breast cancer treatment drug Trodelvy. This acquisition aims to outcompete other large drug makers over securing the number of ownerships of oncology therapies in the portfolio. Also, breast cancer happens to be one of the most lucrative segments of the worldwide cancer therapy market. EvaluatePharma predicts that breast cancer therapy will make $157 million this year.

Related Article: Gilead Adds Jounce to its Long List of Oncology Partnerships

Gilead CEO, Daniel O’Day said, “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer.”

The future success of Trodelvy is optimistic, based on its past records. Trodelvy was granted an accelerated FDA approval in April and sparked $20.1 million net sales in its first two months on the market. According to Jefferies & Co. analytic firm, Trodelvy could become a go-to treatment for triple-negative breast cancer, and its sales will reach $480 million by 2022. According to the joint statement, in the first half of 2021, Immunomedicas will be on track to file for regulator approval for Trodelvy in Europe.

Gilead, Kite, and oNKo-innate Collaborate to Advance Cancer Immunotherapy Using NK Cells

References
  1. https://www.reuters.com/article/us-immunomedics-m-a-gilead-sciences/gilead-to-buy-immunomedics-in-21-billion-deal-idUSKBN2640V8

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
2023-02-14
PDS Buys IL-12 Targeting Therapy From Merck KGaA for $121 Million Biobucks
2023-01-04
GeneOnline’s Pick: Top 10 M&A Deals in 2022
2022-12-28
LATEST
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
2023-03-16
ImmunoPrecise Antibodies, Libera Bio Ink $155 Million Pact To Deliver Antibodies With Nanotechnology
2023-03-16
Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results
2023-03-15
Scroll to Top